Introduction
Multiple pregnancy is associated with significant fetomaternal complications and high cost (Ombelet et al., 2005) . The multiple pregnancy rate (MPR) per cycle of treatment with assisted reproduction technology (ART) is 25% or higher, even in countries where ART is reimbursed (Nygren and Andersen, 2001a,b; Nygren and Andersen, 2002; Andersen et al., 2004; Jones et al., 2011) , much higher than the 1% after natural conception, related to the number of embryos transferred, and preventable by single-embryo transfer (SET) (Gerris et al., 1999; Martikainen et al., 2001; De Neubourg et al., 2002; Tiitinen et al., 2003; Thurin et al., 2004; Saldeen and Sundströ m, 2005) . Since July 2003, in Belgium the laboratory costs for six fresh ART cycles have been reimbursed for female patients younger than 43 years of age and with a Belgian insurance number (Het Belgisch Staatsblad, 2003; Debrock et al., 2005) , but only if a limited number of embryos is transferred, depending on female age and cycle rank. Although this policy has resulted in a significant reduction in the MPR after ART from 24 to 13% without a negative effect on the pregnancy rate (PR) (Belrap, 2002 (Belrap, , 2006 Debrock et al., 2005) , available data are only cycle based and it is unknown what the effect of this legislation is on the cumulative delivery rate (CDR) per patient. The aim of this study was to test the hypothesis that Belgian ART legislation since 2003, coupling reimbursement of laboratory costs to restricted embryo transfer policy, has resulted in a reduced CDR when compared with the situation before 2003.
Materials and Methods

Patient selection
Due to the lack of national patient-based outcome data in the Belgian ART Registry, this retrospective cohort study was performed in the Leuven University Fertility Center, after approval by the Institutional Review Board (ML7701). The study group, patients undergoing a first IVF/ICSI cycle after legislation (1 July 2003 to 30 June 2006), was compared with a control group of patients undergoing a first ART cycle before legislation (1 July 1999 to 30 June 2002). To avoid overlap between groups, patients with first IVF/ICSI cycle within 12 months before legislation (July 2003) were excluded. Patients from the control group who started before July 2002 and who did not discontinue treatment or become pregnant within 12 months (by July 2013) were also excluded. Each patient was followed until six fresh cycles were completed, until delivery (recorded at 20 weeks of gestation (Zegers-Hochschild et al., 2009)) or until discontinuation of treatment before completion of six fresh cycles (Table I) . Reproductive outcome was calculated for each fresh cycle with or without interspersed frozen-thawed embryo transfer (FET) cycles. Cycles without oocytes or sperm, oocyte reception cycles (donor oocyte), embryo reception cycles (donor embryo), and cycles with PGD/preimplantation genetic screening were excluded. Cycles with donor sperm were included if patients used donor sperm during all IVF/ICSI cycles. Cycles from patients who switched from ART treatment with their own gametes to ART treatment with donor gametes or with PGD were included until the moment of switching. All fresh and FET cycles of all patients in the study were chronologically encoded. A mixed cycle-i.e. a cycle where oocyte aspiration was combined with thawing of frozen embryos obtained during previous cycles-was defined as either a fresh or a FET cycle, depending on the origin of the embryos transferred. If pregnancy occurred after a mixed embryo transfer (embryos originating both from oocyte aspiration cycle and from FET cycle), it was linked to the FET cycle.
Ovarian stimulation, oocyte aspiration, embryo culture and embryo transfer Hormonal stimulation, oocyte aspiration, IVF, embryo culture, freezing, thawing and transfer were performed as described before (Debrock et al., 2010; Debrock et al., 2011) . Before legislation, a maximum of two to three embryos were transferred. Since the new legislation in 2003 (Het Belgisch Staatsblad, 2003; Debrock et al., 2005) , embryo transfer is legally restricted depending on female age and cycle rank. In patients younger than 36 years, only one embryo can be transferred in the first cycle regardless of embryo quality; in the second cycle also one embryo is transferred, but two embryos can be transferred if these embryos are of poor quality; in cycles 3 -6, a maximum of two embryos can be transferred. In patients aged 36 -39 years, a maximum of two embryos can be transferred in the first two cycles, and a maximum of three embryos can be transferred in cycle 3 -6. In patients older than 40 years, no legal limitation applies; generally 2 -3 embryos are replaced.
Supernumerary embryos were cryopreserved by the slow freezing procedure or vitrification (Debrock et al., 2011) if their quality was sufficient (2 pronuclei zygotes on Day 1; embryos containing ≥2 cells on Day 2; embryos containing ≥6 cells on Day 3 with ≤25% fragmentation, no multinucleation and with symmetric or slightly asymmetric blastomeres; blastocysts with visible inner cell mass and good trophectoderm layer on Day 5).
Statistical analysis
The CDR, compared between both groups in pessimistic, optimistic and realistic scenarios, was analyzed within six cycles (cycle level) or within 36 months (time level) in the total group, with subanalysis in three relevant age groups (age ,36, 36 -39, 40 -42) (Table I ). Raw CDRs were based on KaplanMeier estimates. Groups were compared using multivariable Cox models including age, body mass index (BMI), duration, type and causes of infertility as confounders known to affect reproductive outcomes after ART. All analyses were performed using SAS version 9.2; P-values ,0.05 were considered statistically significant.
Survival analysis models time-to-event data with censoring. The event in this analysis was pregnancy leading to delivery. Censoring occurred when the time of the event could not be registered for two main reasons: (i) six cycles without success, (ii) treatment discontinuation before the sixth cycle for personal, medical or other reasons.
The optimistic scenario assumed equal probability of pregnancy for couples who discontinued and those who continued treatment while the pessimistic scenario assumed zero probability of pregnancy for discontinuing couples. Since these scenarios lead to over-or underestimation of delivery rate, respectively, a realistic scenario including baseline prognostic information was also used (Collett, 2003 
Continued
ART legislation and cumulative delivery rate received a prognosis code (0 ¼ zero probability of pregnancy, 1 ¼ similar probability of pregnancy as patients continuing treatment), based on embryo quality, a major determinant of reproductive outcome in ART treatment (Alpha Scientists and ESHRE SIG Embryology, 2011). Patients with good quality embryos in the last cycle before discontinuation were defined as 'good prognosis' patients, whereas patients with embryos that did not meet these criteria were defined as 'poor prognosis' patients. A good quality embryo was defined as a 4-, 5-, or 6 cell on Day 2 and a 7-, 8-, or 9 cell on Day 3, with ,10% fragmentation and equally, or slightly unequally, sized blastomeres (Paternot et al., 2009) . A good quality embryo on Day 5 was defined as a blastocyst between the expanding and hatching stages of development, with blastocoele formation in .50% of the embryo, a good inner cell mass (tightly packed, many cells) and a regular trophoblast layer (Debrock et al., 2010) . If the last cycle before discontinuation was a fresh cycle without embryo transfer, the patient was defined to have 'poor prognosis'. If the last cycle before discontinuation was a FET cycle, the prognosis was based on embryo quality of the last fresh ART cycle. If the last cycle before discontinuation was a FET cycle resulting from a fresh cycle in which all embryos were cryopreserved due to risk of ovarian hyperstimulation syndrome, the prognosis of the couple was made based on the quality of the thawed embryos. If the last cycle before discontinuation was a mixed cycle, the prognosis of the patient was based on the embryo quality of the embryo(s) obtained after oocyte aspiration; if only a thawed embryo was used for transfer or no transfer was performed, the patient was assigned to have 'poor prognosis'. The additional contribution of FET cycles was calculated by comparison of CDR survival analysis with and without inclusion of the FET cycles. The CDR without FET cycles was estimated by considering pregnancies after embryo cryopreservation as competing events (Pintilie, 2006) .
To evaluate whether vitrification was a confounder for which correction was needed, we tested the effect of vitrification on delivery rate using logistic regression and generalized estimating equations (GEE) with delivery as a binary outcome and vitrification and number of embryos as predictor variables.
Analysis of the CDR
Multivariable Cox models were used to analyze either time or number of cycles between start of treatment and pregnancy leading to delivery, accounting for discrete event times in the latter case (Allisson, 1995) . Group (study or control) was the predictor of interest; age, BMI, duration, type and causes of infertility were modeled as possible confounders. In case of evidence for non-proportional hazards, extended Cox models were applied with hazard ratios (HR) at 1, 6 and 12 months (time level analysis), or for cycles 1-2 and for cycles 3-6 (cycle level analysis). The cutoff after two cycles was based on the legal restriction to perform SET in the first two cycles of the study group in women younger than 36 years, with expectedly larger differences between groups in these first two cycles.
Analysis of the reproductive outcome data
Chi-square or Fisher exact tests were used to compare both groups regarding percentages of SET, reproductive outcome and discontinuation. When percentages were estimated over all cycles, the relative risk was calculated using a Poisson model with log link and using GEE to account for clustering. The same approach was used for the percentage deliveries per embryo transfer.
Results
We present results after correction for confounding variables age, BMI, duration, type and causes of infertility. Raw data before correction for these confounders are available in Supplementary data, Figs SI and SII. The 95% confidence intervals of the CDRs described below are available in Supplementary data, Table SI.
Patient and cycle characteristics
In total, 1258 patients contributed 3371 (2803 fresh; 568 frozen-thawed) cycles to this study. Table I shows a summary of information on the patients and the cycles. Reproductive outcome data after fresh and FET cycles as well as delivery were available for 100% of the patients (n ¼ 795) in study group and for 99.8% of the patients (462/463) in the control group. There was no correlation between vitrification and delivery rate in FET cycles (P ¼ 0.928).
CDR within 36 months
In the realistic scenario, CDRs within 12 (51 and 59%), 24 (58 and 64%) and 36 (61 and 66%) months were comparable (all ages, P ¼ 0.221) in study and control groups, and when the three age subgroups Results are based on a logistic regression model (blastocysts) or baseline-category logits models (stimulation and treatment) with random intercept to account for clustering.
(,36 years, P ¼ 0.242; 36 -39 years, P ¼ 0.851; 40 -42 years, P ¼ 0.840) were analyzed separately (Fig. 1) . In the pessimistic scenario, evidence was found against the proportional hazards assumption. Therefore HRs were estimated at 1, 6 and 12 months, and CDRs for all ages were comparable between study and control groups (P ¼ 0.206; 0.177; 0.057, respectively). Similar results were found after subanalysis of the age groups.
In the optimistic scenario, CDR within 36 months was slightly lower in study (80%) than in control group (87%, P ¼ 0.047) in all age groups, and in the age group ,36 (P ¼ 0.031, 82 versus 90%). However, the CDR within 36 months was similar for the age groups 36-39 years and 40-42.
CDR within six cycles before and after legislation
In the realistic and pessimistic scenarios evidence was found against the proportional hazards assumption for the total group and for the age group ,36 years (Fig. 2) . Differences in CDR between study and control group, in the form of HRs, were therefore estimated separately for cycles 1-2 and for cycles 3-6.
In the realistic scenario at all ages, CDR within cycles 1-2 was significantly lower in the study group (43%) than in the control group (52%, P ¼ 0.009), but this difference disappeared between cycles 3-6 (P ¼ 0.232) and the overall CDR within six cycles was 60 and 65%, respectively. Similar results were observed in the subgroup ,36 years. The CDR was comparable between study and control groups in age groups 36 -39 years and 40-42 years. Overall, the additional contribution of FET cycles to CDR within six cycles was respectively 6% in study and 7% in control group.
In the pessimistic scenario at all ages, the CDR within cycles 1-2 was significantly lower in study (42%) than in control group (49%, P ¼ 0.030). However, within cycles 3-6, the CDR was significantly higher in the study group than in the control group (P ¼ 0.02). Therefore, CDR within six cycles was similar in study (56%) and control groups (58%). Similar findings were obtained in subgroup ,36. In age groups 36-39 years and 40 -42 years, the CDRs were comparable in both groups. Figure 1 Time level analysis of cumulative delivery rate in Belgium (based on fresh and frozen-thawed cycles) before (control group, straight line) and after (study group, dotted line) introduction of the new legislation to reduce the number of embryos transferred. P-values based on analysis after correction for confounders.
In the optimistic scenario, the CDR within six cycles was significantly lower in study group (72%) than in control group (80%, P ¼ 0.012) in all patients and in the subgroup ,36 years (78 versus 85%, P ¼ 0.004), but comparable in the age groups 36-39 years and 40-42 years.
Reproductive outcome data and discontinuation rate
When compared with control group, study group had a higher proportion of SET cycles (P,0.001), a higher singleton delivery rate (P , 0.001) and a lower twin delivery rate (12 versus 24%, P ¼ , 0.001) ( Table II) . The proportion of patients in the total group who had discontinued ART treatment within six cycles and without pregnancy was lower in the study group (88.4%) than in the control group (94.4%, P ¼ 0.02) ( Table I) .
Discussion
Here, we report for the first time that Belgian public health policy (reimbursement of six ART cycles in combination with a legally restricted number of embryos allowed for transfer) did not have a negative impact on the CDR within six ART cycles or 36 months of ART treatment, based on realistic and pessimistic estimates, in spite of a 50% reduction in MPR (Table II) , and after correction for the confounding variables of age, BMI, duration, type and cause of infertility. Our data are in line with earlier reports showing no reduction of the clinical PR per cycle after the introduction of the Belgian legislation (Debrock et al., 2005; Gordts et al., 2005; Van Landuyt et al., 2006) , but extend these observations to CDR per patient since this outcome variable is generally considered as the gold standard outcome variable for ART treatment.
Although the CDRs reported in our study are comparable with those reported previously (Stolwijk et al., 2000; Olivius et al., 2002; Supplementary data, Table SII) , it is difficult to compare studies due to differences in inclusion criteria (cycles started versus cycles with oocyte aspiration versus cycles with embryo transfer, in-or exclusion of FET cycles, in-or exclusion of ICSI cycles), primary outcome (pregnancy or delivery), secondary outcome (MPR often not reported), duration of Figure 2 Cycle level analysis of cumulative delivery rate in Belgium before (control group, straight line) and after (study group, dotted line) introduction of the new legislation to reduce the number of embryos transferred. Fresh cycles (1 -6) with interspersed frozen embryo transfer cycles but FET cycles were not shown separately on the x-axis. P-values based on analysis after correction for confounders.
follow-up (3-14 cycles), number of embryos transferred (a higher number in most other studies) and statistical analysis (few studies calculated CDR based on realistic estimates) (Supplementary data, Table SII) . Furthermore, it is difficult to compare the reasons influencing discontinuation of ART treatment between centers, due to heterogeneity with respect to inclusion criteria, cost, regulation, reimbursement policies, accessibility to infertility services, patient -doctor communication, access to psychological counseling and support, and loss to follow-up (Van den Broeck et al., 2009; Domar et al., 2010; Boivin et al., 2012) .
An important strength of our study is the calculation of CDR using realistic estimates based on embryo quality, a major determinant of reproductive outcome in ART treatment (Alpha Scientists and ESHRE SIG Embryology, 2011). In only two (Stolwijk et al., 2000; Olivius et al., 2002) out of eight related studies (Supplementary data, Table SII), realistic estimates were also reported, but using arbitrary criteria, without taking into account embryo quality. In the first study (Stolwijk et al., 2000) , realistic cumulative PR was calculated assuming that women who discontinued treatment because of medical reasons had no chance of pregnancy, while those who discontinued for other reasons had the same probability of pregnancy as those who continued. In the second study (Olivius et al., 2002) Comparisons between study and control groups were performed using Chi-square or Fisher exact test, when data were restricted to single cycles. When all cycles were considered, the relative risk was estimated using a Poisson model with log link and based on generalized estimating equations (GEE) to account for clustering of cycles within patients. The relative risk was estimated using a Poisson model with log link and based on GEE to account for clustering of cycles within patients.
because of poor prognosis had no probability of achieving a live birth whereas all other women who discontinued treatment for other reasons had the same probability of a live birth as women who continued treatment. However, poor prognosis was not defined in Olivius et al. (2002) . In our study, it can be criticized that only prognosis code 0 or 1 was used, thereby excluding a group of patients with a better than average prognosis which may have led to an underestimation of the chance of pregnancy for certain patients.
Another strength of our study is calculation of the CDR over a long period of time (12-36 months), which is more relevant than calculation of the CDR within a specific number of cycles (Eijkemans et al., 2006) . Time to pregnancy resulting in live birth can be used as an important outcome indicator target to improve ART treatment effectiveness for patients, clinicians, embryologists, nurses/midwives, health economists and policy makers (Heijnen et al., 2004; Dancet et al., 2013) .
Our data appear to be representative for all Belgian centers. This is important, as it is impossible to calculate the effect of Belgian legislation on the CDR per patient using nationally registered Belgian ART data based on cycle level, not patient level, up until 2012 (http://www.belrap.be). Firstly, median age of our patients was comparable with median age of patients treated in Belgium during the same time period (33 years (1999-2002) and 34 years (2003) (2004) (2005) (2006) ; http://www.belrap.be). Secondly, our patients were representative for the Belgian population with respect to the 2-fold reduction in MPR after legislation (24% (2002) . Thirdly, when compared with the situation before legislation, PR per cycle was reduced by 2-5% after legislation in our center (Debrock et al., 2005) , just like in other Belgian centers (Van Landuyt et al., 2006; Salame et al., 2007) . Due to the retrospective character of this analysis over a long period of time, it is clear that our data are potentially influenced by improvements in techniques and subsequently improved success rates in ART over time. In countries without a mandatory SET policy, such as the USA, registration data from the Society for Assisted Reproductive Technology demonstrate a significant increase in the live birth deliveries per number of fresh embryo transfers (33% in 1999-2002 and 34.6% in 2003 -2006 , P , 0.0001) and per number of FETs (22.1% in 1999 FETs (22.1% in -2002 FETs (22.1% in and 28% in 2003 FETs (22.1% in -2006 , P , 0.001) (http://www.cdc.gov/mmwr/mmwr_ss/ ss_pvol.html) (Supplementary data, Table SIII) .
It is not clear why, among patients who did not become pregnant during ART treatment, the number of patients who discontinued treatment before the sixth cycle was lower in the study group than in the control group. We hypothesize that patients in the study group, who were entitled to ART reimbursement for a maximum of six cycles on total, were more likely to continue treatment than patients from the control group who did not have laboratory reimbursement.
The results of our paper have implications for public health policies worldwide with respect to quality, safety, regulation and financial control of treatments with ART. From a public health point of view, the 'Belgian model' can now be considered by other governments for application worldwide. In countries without ART reimbursement, the Belgian model with restricted embryo transfer policy can be used to achieve at least a 50% reduction in MPR and associated public health costs, with no negative impact on the CDR per patient, quite relevant for patients who have to pay ART treatment themselves. The substantial amount of money saved by this policy can be used ideally to improve patient access to ART by selective reimbursement.
In conclusion, this study showed that Belgian legislation combining reimbursement of six ART cycles with a legally enforced reduction in the number of embryos transferred did not have a negative impact on the CDR within six ART cycles or 36 months of ART treatment, based on realistic or pessimistic estimates, in spite of a 50% reduction in MPR from 24 to 12%. This 'Belgian model' can now be considered for application worldwide in countries with the aim to reduce the main ART side effect (high MPR) and its associated costs without introducing a negative effect on the main intended effect (high CDR).
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
